Runx2-Smad signaling impacts the progression of tumor-induced bone disease

International Journal of Cancer

Volumn 136, Issue 6, 2015, Pages 1321-1332

  Zhang, Xuhui ^a,b   Akech, Jacqueline ^b   Browne, Gillian ^a,b   Russell, Stacey ^b   Wixted, John J ^b   Stein, Janet L ^a,b   Stein, Gary S ^a,b   Lian, Jane B ^a,b  

^a UNIVERSITY OF VERMONT COLLEGE OF MEDICINE   (United States)

^b UNIVERSITY OF MASSACHUSETTS MEDICAL SCHOOL   (United States)

Author keywords

Intratibial tumors; Metastatic bone disease; Osteoblastic osteolytic disease; Prostate cancer; Runx2

Indexed keywords

SMAD PROTEIN; TRANSCRIPTION FACTOR RUNX2; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; OSTEOPONTIN; RUNX2 PROTEIN, HUMAN;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BIOLUMINESCENCE; BONE LESION; BONE METASTASIS; BONE RADIOGRAPHY; CANCER GROWTH; CARBOXY TERMINAL SEQUENCE; CARCINOGENESIS; CELL ADHESION; GENE DELETION; GENE TARGETING; LUNG METASTASIS; MALE; MICRO-COMPUTED TOMOGRAPHY; NONHUMAN; OSSIFICATION; OSTEOBLAST; OSTEOLYSIS; POINT MUTATION; PROSTATE CANCER; PROSTATE CANCER CELL LINE; PROTEIN PROTEIN INTERACTION; RAT; SIGNAL TRANSDUCTION; TUMOR INVASION; TUMOR MICROENVIRONMENT; TUMOR VOLUME; ANIMAL; BONE DISEASES; COMPLICATION; DISEASE COURSE; GENETICS; HUMAN; MOUSE; PHYSIOLOGY; PROSTATE TUMOR; TUMOR CELL LINE;

ANIMALS; BONE DISEASES; CELL LINE, TUMOR; CORE BINDING FACTOR ALPHA 1 SUBUNIT; DISEASE PROGRESSION; GRANULOCYTE-MACROPHAGE COLONY-STIMULATING FACTOR; HUMANS; MALE; MICE; OSTEOPONTIN; PROSTATIC NEOPLASMS; SIGNAL TRANSDUCTION; SMAD PROTEINS;

EID: 84922216464     PISSN: 00207136     EISSN: 10970215     Source Type: Journal    
DOI: 10.1002/ijc.29094     Document Type: Article

References (50)

1. American Cancer Society. Cancer facts and figures 2012. Atlanta, GA: American Cancer Society, 2012. 68p.
2. Rizzoli R, Body JJ, Brandi ML, et al. Cancer-associated bone disease. Osteoporos Int 2013;24:2929-53.
3. Pratap J, Lian JB, Stein GS. Metastatic bone disease: role of transcription factors and future targets. Bone 2011;48:30-6.
4. Akech J, Wixted JJ, Bedard K, et al. Runx2 association with progression of prostate cancer in patients: mechanisms mediating bone osteolysis and osteoblastic metastatic lesions. Oncogene 2010;29:811-21.
5. Jiang Y, Dai J, Zhang H, et al. Activation of the Wnt pathway through AR79, a GSK3beta inhibitor, promotes prostate cancer growth in soft tissue and bone. Mol Cancer Res 2013;11:1597-610.
6. Viticchie G, Lena AM, Latina A, et al. MiR-203 controls proliferation, migration and invasive potential of prostate cancer cell lines. Cell Cycle 2011;10:1121-31.
7. Zhang H, Pan Y, Zheng L, et al. FOXO1 inhibits Runx2 transcriptional activity and prostate cancer cell migration and invasion. Cancer Res 2011;71:3257-67.
8. Lynch CC. Matrix metalloproteinases as master regulators of the vicious cycle of bone metastasis. Bone 2011;48:44-53.
9. Gordon JA, Sodek J, Hunter GK, et al. Bone sialoprotein stimulates focal adhesion-related signaling pathways: role in migration and survival of breast and prostate cancer cells. J Cell Biochem 2009;107:1118-28.
10. Tilli TM, Mello KD, Ferreira LB, et al. Both osteopontin-c and osteopontin-b splicing isoforms exert pro-tumorigenic roles in prostate cancer cells. Prostate 2012;72:1688-99.
11. Pratap J, Javed A, Languino LR, et al. The Runx2 osteogenic transcription factor regulates matrix metalloproteinase 9 in bone metastatic cancer cells and controls cell invasion. Mol Cell Biol 2005;25:8581-91.
12. Baniwal SK, Khalid O, Gabet Y, et al. Runx2 transcriptome of prostate cancer cells: insights into invasiveness and bone metastasis. Mol Cancer 2010;9:258.
13. Lim M, Zhong C, Yang S, et al. Runx2 regulates survivin expression in prostate cancer cells. Lab Invest 2010;90:222-33.
14. Pratap J, Wixted JJ, Gaur T, et al. Runx2 transcriptional activation of Indian Hedgehog and a downstream bone metastatic pathway in breast cancer cells. Cancer Res 2008;68:7795-802.
15. Chen YC, Sosnoski DM, Mastro AM. Breast cancer metastasis to the bone: mechanisms of bone loss. Breast Cancer Res 2010;12:215.
16. Sottnik JL, Keller ET. Understanding and targeting osteoclastic activity in prostate cancer bone metastases. Curr Mol Med 2013;13:626-39.
17. Dutta A, Li J, Lu H, et al. Integrin alphavbeta6 promotes an osteolytic program in cancer cells by upregulating MMP2. Cancer Res 2014;74:1598-608.
18. Weilbaecher KN, Guise TA, McCauley LK. Cancer to bone: a fatal attraction. Nat Rev Cancer 2011;11:411-25.
19. Buijs JT, Stayrook KR, Guise TA. TGF-beta in the bone microenvironment: role in breast cancer metastases. Cancer Microenviron 2011;4:261-81.
20. Padua D, Massague J. Roles of TGFbeta in metastasis. Cell Res 2009;19:89-102.
21. Afzal F, Pratap J, Ito K, et al. Smad function and intranuclear targeting share a Runx2 motif required for osteogenic lineage induction and BMP2 responsive transcription. J Cell Physiol 2005;204:63-72.
22. Javed A, Bae JS, Afzal F, et al. Structural coupling of Smad and Runx2 for execution of the BMP2 osteogenic signal. J Biol Chem 2008;283:8412-22.
23. Lee KS, Kim HJ, Li QL, et al. Runx2 is a common target of transforming growth factor beta1 and bone morphogenetic protein 2, and cooperation between Runx2 and Smad5 induces osteoblast-specific gene expression in the pluripotent mesenchymal precursor cell line C2C12. Mol Cell Biol 2000;20:8783-92.
24. Gupta A, Cao W, Chellaiah MA. Integrin alphavbeta3 and CD44 pathways in metastatic prostate cancer cells support osteoclastogenesis via a Runx2/Smad 5/receptor activator of NF-kappaB ligand signaling axis. Mol Cancer 2012;11:66.
25. Zhang YW, Yasui N, Ito K, et al. A RUNX2/PEB-P2alpha A/CBFA1 mutation displaying impaired transactivation and Smad interaction in cleidocranial dysplasia. Proc Natl Acad Sci USA 2000;97:10549-54.
26. Schroeder TM, Jensen ED, Westendorf JJ. Runx2: a master organizer of gene transcription in developing and maturing osteoblasts. Birth Defects Res C Embryo Today 2005;75:213-25.
27. Zaidi SK, Sullivan AJ, van Wijnen AJ, et al. Integration of Runx and Smad regulatory signals at transcriptionally active subnuclear sites. Proc Natl Acad Sci USA 2002;99:8048-53.
28. Choi JY, Pratap J, Javed A, et al. Subnuclear targeting of Runx/Cbfa/AML factors is essential for tissue-specific differentiation during embryonic development. Proc Natl Acad Sci USA 2001;98:8650-5.
29. Campbell JP, Merkel AR, Masood-Campbell SK, et al. Models of bone metastasis. J Vis Exp 2012;67:e4260.
30. Wai PY, Mi Z, Gao C, et al. Ets-1 and Runx2 regulate transcription of a metastatic gene, osteopontin, in murine colorectal cancer cells. J Biol Chem 2006;281:18973-82.
31. McCoy EM, Hong H, Pruitt HC, et al. IL-11 produced by breast cancer cells augments osteoclastogenesis by sustaining the pool of osteoclast progenitor cells. BMC Cancer 2013;13:16.
32. Guise TA, Mohammad KS, Clines G, et al. Basic mechanisms responsible for osteolytic and osteoblastic bone metastases. Clin Cancer Res 2006;12:6213s-6216s.
33. Lotinun S, Kiviranta R, Matsubara T, et al. Osteoclast-specific cathepsin K deletion stimulates S1P-dependent bone formation. J Clin Invest 2013;123:666-81.
34. Lacey DL, Boyle WJ, Simonet WS, et al. Bench to bedside: elucidation of the OPG-RANK-RANKL pathway and the development of denosumab. Nat Rev Drug Discov 2012;11:401-19.
35. Kitagawa Y, Dai J, Zhang J, et al. Vascular endothelial growth factor contributes to prostate cancer-mediated osteoblastic activity. Cancer Res 2005;65:10921-9.
36. Bagri A, Berry L, Gunter B, et al. Effects of anti-VEGF treatment duration on tumor growth, tumor regrowth, and treatment efficacy. Clin Cancer Res 2010;16:3887-900.
37. Karnezis T, Shayan R, Caesar C, et al. VEGF-D promotes tumor metastasis by regulating prostaglandins produced by the collecting lymphatic endothelium. Cancer Cell 2012;21:181-95.
38. Jorgenson E, Deitcher SR, Cicek M, et al. Plasminogen activator inhibitor type-1 (PAI-1) polymorphism 4G/5G is associated with prostate cancer among men with a positive family history. Prostate 2007;67:172-7.
39. Pal S, Ganguly KK, Chatterjee A. Extracellular matrix protein fibronectin induces matrix metalloproteinases in human prostate adenocarcinoma cells PC-3. Cell Commun Adhes 2013;20:105-14.
40. Yun SJ, Yoon HY, Bae SC, et al. Transcriptional repression of RUNX2 is associated with aggressive clinicopathological outcomes, whereas nuclear location of the protein is related to metastasis in prostate cancer. Prostate Cancer Prostatic Dis 2012;15:369-73.
41. Brubaker KD, Vessella RL, Brown LG, et al. Prostate cancer expression of runt-domain transcription factor Runx2, a key regulator of osteoblast differentiation and function. Prostate 2003;56:13-22.
42. Jia D, Entersz I, Butler C, et al. Fibronectin matrix-mediated cohesion suppresses invasion of prostate cancer cells. BMC Cancer 2012;12:94.
43. Mendoza-Villanueva D, Zeef L, Shore P. Metastatic breast cancer cells inhibit osteoblast differentiation through the Runx2/CBFbeta-dependent expression of the Wnt antagonist, sclerostin. Breast Cancer Res 2011;13:R106.
44. Enomoto H, Shiojiri S, Hoshi K, et al. Induction of osteoclast differentiation by Runx2 through receptor activator of nuclear factor-kappa B ligand (RANKL) and osteoprotegerin regulation and partial rescue of osteoclastogenesis in Runx2-/- mice by RANKL transgene. J Biol Chem 2003;278:23971-7.
45. Zelzer E, Glotzer DJ, Hartmann C, et al. Tissue specific regulation of VEGF expression during bone development requires Cbfa1/Runx2. Mech Dev 2001;106:97-106.
46. Liu Y, Berendsen AD, Jia S, et al. Intracellular VEGF regulates the balance between osteoblast and adipocyte differentiation. J Clin Invest 2012;122:3101-13.
47. Bae SC, Lee YH. Phosphorylation, acetylation and ubiquitination: the molecular basis of RUNX regulation. Gene 2006;366:58-66.
48. Li J, Karaplis AC, Huang DC, et al. PTHrP drives breast tumor initiation, progression, and metastasis in mice and is a potential therapy target. J Clin Invest 2011;121:4655-69.
49. Martin TJ. Osteoblast-derived PTHrP is a physiological regulator of bone formation. J Clin Invest 2005;115:2322-4.
50. Luker KE, Lewin SA, Mihalko LA, et al. Scavenging of CXCL12 by CXCR7 promotes tumor growth and metastasis of CXCR4-positive breast cancer cells. Oncogene 2012;31:4750-8.